Praziquantel 600 mg Section 19A Approval – Now Available from Pro Pharmaceuticals Group
- @propharmgroup
- Sep 3
- 1 min read
Dear Healthcare Professional,
Discontinuation of BILTRICIDE® (Praziquantel 600 mg tablets, AUST R: 18845)
Pro Pharmaceuticals Group acknowledges the discontinuation of the Australian registered product BILTRICIDE® (Praziquantel 600 mg tablet bottle, AUST R: 18845).
To support ongoing patient care and minimise disruption, Pro Pharmaceuticals Group has secured supply of an alternative product – Praziquantel tablets, USP 600 mg (Endo, USA) – under approval granted by the TGA in accordance with Section 19A of the Therapeutic Goods Act 1989.
This Section 19A approval is valid until 31 March 2027.
Key details:
Active ingredient and strength are identical to the discontinued Australian product.
Registered and marketed in the United States; labelled in English.
Approved for use in the treatment of schistosoma infections (Schistosoma haematobium, S. japonicum, S. mekongi, S. mansoni).
Supplied in packs of 6 tablets.
We encourage hospital pharmacies, infectious diseases units, and community pharmacists to share this information internally and contact us regarding supply.
📧 For orders or further enquiries, please email: orders@propg.com.au🌐 Or visit: www.propg.com.au
